Patents by Inventor Kemal Baysal

Kemal Baysal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MICROFLUIDIC PLATFORM FOR ENABLING CELL CULTURING IN A THREE DIMENSIONAL MICROENVIRONMENT
    Publication number: 20220364029
    Abstract: A three dimensional (3D) microfluidic cartridge suitable for reproduction of cells in the 3D microfluidic cartridge and for observing an angiogenesis process is provided. The 3D microfluidic cartridge includes a side area, wherein a height of the side area is greater than a height of central area. With the 3D microfluidic cartridge, a 3D cell culture is carried out, tumor spheroids are formed in the 3D microfluidic cartridge, and angiogenesis potentials of the tumor spheroids are measured. Further, responses of endothelial cells against angiogenic or antiangiogenic effects of various small molecules, drugs, and protein therapeutics are measured in the 3D microfluidic cartridge.
    Type: Application
    Filed: June 17, 2020
    Publication date: November 17, 2022
    Applicants: KOC UNIVERSITESI, ISTANBUL TEKNIK UNIVERSITESI
    Inventors: Alper KIRAZ, Kemal BAYSAL, Ahmet C ERTEN, Berna MOROVA, Ateeq UR REHMAN, Umut Can COSKUN
  • Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (VEGFR—2/KDR)
    Patent number: 9193792
    Abstract: Phage displayed recombinant antibody library was developed and the library was screened against VEGFR-2. After screening and ELISA experiments two recombinant antibodies showing binding properties to VEGFR-2 was obtained. The difference of the two recombinant antibodies to the recombinant antibodies already developed was demonstrated by DNA sequence analysis. The inhibition effect of the two recombinant antibodies on endothelial cell proliferation was demonstrated with cell assays. Thus these recombinant antibodies might be used as VEGF related angiogenesis inhibitors.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: November 24, 2015
    Assignee: TUBITAK
    Inventors: Berrin Erda{hacek over (g)}, Bertan Koray Balcio{hacek over (g)}lu, Aylin Ozdemir Bahadir, Aydin Bahar, Kemal Baysal, Müge Serhatli, Omer Kaçar, Türker Kiliç, Emel Akgün, Abdulkadir Özkan
  • RECOMBINANT ANTIBODY STRUCTURES BINDING TO AND BLOCKING THE ACTIVITY OF VASCULAR ENDOTHELIAL GROWTH FACTOR 2 (VEGFR- 2/KDR)
    Publication number: 20140199301
    Abstract: Phage displayed recombinant antibody library was developed and the library was screened against VEGFR-2. After screening and ELISA experiments two recombinant antibodies showing binding properties to VEGFR-2 was obtained. The difference of the two recombinant antibodies to the recombinant antibodies already developed was demonstrated by DNA sequence analysis. The inhibition effect of the two recombinant antibodies on endothelial cell proliferation was demonstrated with cell assays. Thus these recombinant antibodies might be used as VEGF related angiogenesis inhibitors.
    Type: Application
    Filed: July 7, 2010
    Publication date: July 17, 2014
    Applicant: TUBITAK
    Inventors: Berrin Erdag, Bertan Koray Balcioglu, Aylin Ozdemir Bahadir, Aydin Bahar, Kemal Baysal, Müge Serhatli, Omer Kaçar, Turker Kiliç, Emel Akgün, Abdulkadir Özkan